 | • レポートコード：MRC2102QY11796 • 出版社/出版日： / 2021年1月 • レポート形態：英文、PDF、141ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品、医療 |
| Single User | ￥592,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥888,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,184,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYリサーチ社の本調査レポートでは、世界の肺動脈性肺高血圧症（PAH）治療薬市場について種類別（吸入、注射剤、経口投与）、用途別（病院、診療所、その他）、地域別（米国、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。 ・肺動脈性肺高血圧症（PAH）治療薬市場の概要 ・世界の主要地域別肺動脈性肺高血圧症（PAH）治療薬市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の肺動脈性肺高血圧症（PAH）治療薬市場規模2015-2026：種類別（吸入、注射剤、経口投与） ・世界の肺動脈性肺高血圧症（PAH）治療薬市場規模2015-2026：用途別（病院、診療所、その他） ・肺動脈性肺高血圧症（PAH）治療薬の米国市場規模2015-2020 ・肺動脈性肺高血圧症（PAH）治療薬のヨーロッパ市場規模2015-2020 ・肺動脈性肺高血圧症（PAH）治療薬の中国市場規模2015-2020 ・肺動脈性肺高血圧症（PAH）治療薬の日本市場規模2015-2020 ・肺動脈性肺高血圧症（PAH）治療薬の東南アジア市場規模2015-2020 ・肺動脈性肺高血圧症（PAH）治療薬のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 ・肺動脈性肺高血圧症（PAH）治療薬の製造コスト分析 ・販売チャネル、流通業者、顧客 ・肺動脈性肺高血圧症（PAH）治療薬の市場動向・機会・課題 ・調査の結論 |
Market Analysis and Insights: Global Pulmonary Arterial Hypertension (PAH) Drugs Market
The global Pulmonary Arterial Hypertension (PAH) Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
Global Pulmonary Arterial Hypertension (PAH) Drugs Scope and Market Size
The global Pulmonary Arterial Hypertension (PAH) Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Pulmonary Arterial Hypertension (PAH) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.
Segment by Type, the Pulmonary Arterial Hypertension (PAH) Drugs market is segmented into
Inhalation
Injectables
Oral Administration
Segment by Application, the Pulmonary Arterial Hypertension (PAH) Drugs market is segmented into
Hospitals
Clinics
Other
The Pulmonary Arterial Hypertension (PAH) Drugs market is analysed and market size information is provided by regions (countries). Segment by Application, the Pulmonary Arterial Hypertension (PAH) Drugs market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Pulmonary Arterial Hypertension (PAH) Drugs Market Share Analysis
Pulmonary Arterial Hypertension (PAH) Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Pulmonary Arterial Hypertension (PAH) Drugs business, the date to enter into the Pulmonary Arterial Hypertension (PAH) Drugs market, Pulmonary Arterial Hypertension (PAH) Drugs product introduction, recent developments, etc.
The major vendors covered:
Pfizer
Glaxosmithkline
Novartis
United Therapeutics
AstraZeneca
Merck
Bayer Healthcare
Actelion Pharmaceuticals
Daiichi Sankyo
Northern Therapeutics
Aires Pharmaceuticals
Arena Pharmaceuticals
Berlin Cures
Eiger BioPharmaceuticals
Reata Pharmaceuticals
1 Pulmonary Arterial Hypertension (PAH) Drugs Market Overview
1.1 Pulmonary Arterial Hypertension (PAH) Drugs Product Scope
1.2 Pulmonary Arterial Hypertension (PAH) Drugs Segment by Type
1.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2020-2026)
1.2.2 Inhalation
1.2.3 Injectables
1.2.4 Oral Administration
1.3 Pulmonary Arterial Hypertension (PAH) Drugs Segment by Application
1.3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Comparison by Application (2020-2026)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Pulmonary Arterial Hypertension (PAH) Drugs Market Estimates and Forecasts (2015-2026)
1.4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (2015-2026)
1.4.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2015-2026)
1.4.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Price Trends (2015-2026)
2 Pulmonary Arterial Hypertension (PAH) Drugs Estimate and Forecast by Region
2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region (2015-2020)
2.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region (2015-2020)
2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Estimates and Projections (2015-2026)
2.4.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Estimates and Projections (2015-2026)
2.4.3 China Pulmonary Arterial Hypertension (PAH) Drugs Estimates and Projections (2015-2026)
2.4.4 Japan Pulmonary Arterial Hypertension (PAH) Drugs Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Estimates and Projections (2015-2026)
2.4.6 India Pulmonary Arterial Hypertension (PAH) Drugs Estimates and Projections (2015-2026)
3 Global Pulmonary Arterial Hypertension (PAH) Drugs Competition Landscape by Players
3.1 Global Top Pulmonary Arterial Hypertension (PAH) Drugs Players by Sales (2015-2020)
3.2 Global Top Pulmonary Arterial Hypertension (PAH) Drugs Players by Revenue (2015-2020)
3.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pulmonary Arterial Hypertension (PAH) Drugs as of 2019)
3.4 Global Pulmonary Arterial Hypertension (PAH) Drugs Average Price by Company (2015-2020)
3.5 Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Pulmonary Arterial Hypertension (PAH) Drugs Players (Opinion Leaders)
4 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Type
4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Historic Market Review by Type (2015-2020)
4.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2015-2020)
4.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2015-2020)
4.1.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2015-2020)
4.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Price Forecast by Type (2021-2026)
5 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Application
5.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Historic Market Review by Application (2015-2020)
5.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2015-2020)
5.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2015-2020)
5.1.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2015-2020)
5.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Price Forecast by Application (2021-2026)
6 United States Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures
6.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Company (2015-2020)
6.2 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2015-2020)
6.3 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2015-2020)
7 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures
7.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Company (2015-2020)
7.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2015-2020)
7.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2015-2020)
8 China Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures
8.1 China Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Company (2015-2020)
8.2 China Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2015-2020)
8.3 China Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2015-2020)
9 Japan Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures
9.1 Japan Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Company (3015-3030)
9.2 Japan Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2015-2020)
9.3 Japan Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2015-2020)
10 Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures
10.1 Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Company (2015-2020)
10.2 Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2015-2020)
10.3 Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2015-2020)
11 India Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures
11.1 India Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Company (2015-2020)
11.2 India Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2015-2020)
11.3 India Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Pulmonary Arterial Hypertension (PAH) Drugs Business
12.1 Pfizer
12.1.1 Pfizer Corporation Information
12.1.2 Pfizer Business Overview
12.1.3 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
12.1.5 Pfizer Recent Development
12.2 Glaxosmithkline
12.2.1 Glaxosmithkline Corporation Information
12.2.2 Glaxosmithkline Business Overview
12.2.3 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
12.2.5 Glaxosmithkline Recent Development
12.3 Novartis
12.3.1 Novartis Corporation Information
12.3.2 Novartis Business Overview
12.3.3 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
12.3.5 Novartis Recent Development
12.4 United Therapeutics
12.4.1 United Therapeutics Corporation Information
12.4.2 United Therapeutics Business Overview
12.4.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.4.4 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
12.4.5 United Therapeutics Recent Development
12.5 AstraZeneca
12.5.1 AstraZeneca Corporation Information
12.5.2 AstraZeneca Business Overview
12.5.3 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.5.4 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
12.5.5 AstraZeneca Recent Development
12.6 Merck
12.6.1 Merck Corporation Information
12.6.2 Merck Business Overview
12.6.3 Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Merck Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
12.6.5 Merck Recent Development
12.7 Bayer Healthcare
12.7.1 Bayer Healthcare Corporation Information
12.7.2 Bayer Healthcare Business Overview
12.7.3 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
12.7.5 Bayer Healthcare Recent Development
12.8 Actelion Pharmaceuticals
12.8.1 Actelion Pharmaceuticals Corporation Information
12.8.2 Actelion Pharmaceuticals Business Overview
12.8.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
12.8.5 Actelion Pharmaceuticals Recent Development
12.9 Daiichi Sankyo
12.9.1 Daiichi Sankyo Corporation Information
12.9.2 Daiichi Sankyo Business Overview
12.9.3 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
12.9.5 Daiichi Sankyo Recent Development
12.10 Northern Therapeutics
12.10.1 Northern Therapeutics Corporation Information
12.10.2 Northern Therapeutics Business Overview
12.10.3 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
12.10.5 Northern Therapeutics Recent Development
12.11 Aires Pharmaceuticals
12.11.1 Aires Pharmaceuticals Corporation Information
12.11.2 Aires Pharmaceuticals Business Overview
12.11.3 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
12.11.5 Aires Pharmaceuticals Recent Development
12.12 Arena Pharmaceuticals
12.12.1 Arena Pharmaceuticals Corporation Information
12.12.2 Arena Pharmaceuticals Business Overview
12.12.3 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.12.4 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
12.12.5 Arena Pharmaceuticals Recent Development
12.13 Berlin Cures
12.13.1 Berlin Cures Corporation Information
12.13.2 Berlin Cures Business Overview
12.13.3 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.13.4 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
12.13.5 Berlin Cures Recent Development
12.14 Eiger BioPharmaceuticals
12.14.1 Eiger BioPharmaceuticals Corporation Information
12.14.2 Eiger BioPharmaceuticals Business Overview
12.14.3 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.14.4 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
12.14.5 Eiger BioPharmaceuticals Recent Development
12.15 Reata Pharmaceuticals
12.15.1 Reata Pharmaceuticals Corporation Information
12.15.2 Reata Pharmaceuticals Business Overview
12.15.3 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.15.4 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
12.15.5 Reata Pharmaceuticals Recent Development
13 Pulmonary Arterial Hypertension (PAH) Drugs Manufacturing Cost Analysis
13.1 Pulmonary Arterial Hypertension (PAH) Drugs Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH) Drugs
13.4 Pulmonary Arterial Hypertension (PAH) Drugs Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Pulmonary Arterial Hypertension (PAH) Drugs Distributors List
14.3 Pulmonary Arterial Hypertension (PAH) Drugs Customers
15 Market Dynamics
15.1 Pulmonary Arterial Hypertension (PAH) Drugs Market Trends
15.2 Pulmonary Arterial Hypertension (PAH) Drugs Opportunities and Drivers
15.3 Pulmonary Arterial Hypertension (PAH) Drugs Market Challenges
15.4 Pulmonary Arterial Hypertension (PAH) Drugs Market Restraints
15.5 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) Growth Rate by Type (2020-2026) (US$ Million)
Table 2. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) Comparison by Application (2020-2026) (US$ Million)
Table 3. Global Market Pulmonary Arterial Hypertension (PAH) Drugs Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 4. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) by Region (2015-2020)
Table 5. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region (2015-2020)
Table 6. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$ Million) Market Share by Region (2015-2020))
Table 7. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Region (2015-2020)
Table 8. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) Forecast by Region (2021-2026)
Table 9. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share Forecast by Region (2021-2026)
Table 10. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$ Million) Forecast by Region (2021-2026)
Table 11. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share Forecast by Region (2021-2026)
Table 12. Global Pulmonary Arterial Hypertension (PAH) Drugs (K Pcs) of Key Companies (2015-2020)
Table 13. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Company (2015-2020)
Table 14. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$ Million) by Company (2015-2020)
Table 15. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Company (2015-2020)
Table 16. Global Pulmonary Arterial Hypertension (PAH) Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pulmonary Arterial Hypertension (PAH) Drugs as of 2019)
Table 17. Global Pulmonary Arterial Hypertension (PAH) Drugs Average Price (USD/Pcs) of Key Company (2015-2020)
Table 18. Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Manufacturing Sites and Area Served
Table 19. Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Main Points Interviewed from Key Pulmonary Arterial Hypertension (PAH) Drugs Players
Table 22. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) by Type (2015-2020)
Table 23. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Type (2015-2020)
Table 24. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$ Million) Market Share by Type (2015-2020)
Table 25. Global Pulmonary Arterial Hypertension (PAH) Drugs Price (K Pcs) by Type (2015-2020)
Table 26. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Type (2021-2026)
Table 27. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$ Million) Market Share by Type (2021-2026)
Table 28. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Type (2021-2026)
Table 29. Global Pulmonary Arterial Hypertension (PAH) Drugs Price (K Pcs) by Type (2021-2026)
Table 30. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) by Application (2015-2020)
Table 31. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Application (2015-2020)
Table 32. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$ Million) Market Share by Application (2015-2020)
Table 33. Global Pulmonary Arterial Hypertension (PAH) Drugs Price (K Pcs) by Application (2015-2020)
Table 34. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) by Application (2021-2026)
Table 35. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Application (2021-2026)
Table 36. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$ Million) Market Share by Application (2021-2026)
Table 37. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Application (2021-2026)
Table 38. Global Pulmonary Arterial Hypertension (PAH) Drugs Price (K Pcs) by Application (2021-2026)
Table 39. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) by Company (2015-2020)
Table 40. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Company (2015-2020)
Table 41. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) by Type (2015-2020)
Table 42. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2015-2020)
Table 43. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) by Application (2015-2020)
Table 44. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2015-2020)
Table 45. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) by Company (2015-2020)
Table 46. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Company (2015-2020)
Table 47. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) by Type (2015-2020)
Table 48. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2015-2020)
Table 49. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) by Application (2015-2020)
Table 50. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2015-2020)
Table 51. China Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) by Company (2015-2020)
Table 52. China Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Company (2015-2020)
Table 53. China Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) by Type (2015-2020)
Table 54. China Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2015-2020)
Table 55. China Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) by Application (2015-2020)
Table 56. China Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2015-2020)
Table 57. Japan Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) by Company (2015-2020)
Table 58. Japan Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Company (2015-2020)
Table 59. Japan Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) by Type (2015-2020)
Table 60. Japan Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2015-2020)
Table 61. Japan Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) by Application (2015-2020)
Table 62. Japan Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2015-2020)
Table 63. Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) by Company (2015-2020)
Table 64. Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Company (2015-2020)
Table 65. Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) by Type (2015-2020)
Table 66. Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2015-2020)
Table 67. Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) by Type (2015-2020)
Table 68. Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2015-2020)
Table 69. India Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) by Company (2015-2020)
Table 70. India Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Company (2015-2020)
Table 71. India Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) by Type (2015-2020)
Table 72. India Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2015-2020)
Table 73. India Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) by Application (2015-2020)
Table 74. India Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2015-2020)
Table 75. Pfizer Corporation Information
Table 76. Pfizer Description and Business Overview
Table 77. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 78. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 79. Pfizer Recent Development
Table 80. Glaxosmithkline Corporation Information
Table 81. Glaxosmithkline Description and Business Overview
Table 82. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 83. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 84. Glaxosmithkline Recent Development
Table 85. Novartis Corporation Information
Table 86. Novartis Description and Business Overview
Table 87. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 88. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 89. Novartis Recent Development
Table 90. United Therapeutics Corporation Information
Table 91. United Therapeutics Description and Business Overview
Table 92. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 93. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 94. United Therapeutics Recent Development
Table 95. AstraZeneca Corporation Information
Table 96. AstraZeneca Description and Business Overview
Table 97. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 98. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 99. AstraZeneca Recent Development
Table 100. Merck Corporation Information
Table 101. Merck Description and Business Overview
Table 102. Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 103. Merck Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 104. Merck Recent Development
Table 105. Bayer Healthcare Corporation Information
Table 106. Bayer Healthcare Description and Business Overview
Table 107. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 108. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 109. Bayer Healthcare Recent Development
Table 110. Actelion Pharmaceuticals Corporation Information
Table 111. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 112. Actelion Pharmaceuticals Description and Business Overview
Table 113. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 114. Actelion Pharmaceuticals Recent Development
Table 115. Daiichi Sankyo Corporation Information
Table 116. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 117. Daiichi Sankyo Description and Business Overview
Table 118. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 119. Daiichi Sankyo Recent Development
Table 120. Northern Therapeutics Corporation Information
Table 121. Northern Therapeutics Description and Business Overview
Table 122. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 123. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 124. Northern Therapeutics Recent Development
Table 125. Aires Pharmaceuticals Corporation Information
Table 126. Aires Pharmaceuticals Description and Business Overview
Table 127. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 128. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 129. Aires Pharmaceuticals Recent Development
Table 130. Arena Pharmaceuticals Corporation Information
Table 131. Arena Pharmaceuticals Description and Business Overview
Table 132. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 133. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 134. Arena Pharmaceuticals Recent Development
Table 135. Berlin Cures Corporation Information
Table 136. Berlin Cures Description and Business Overview
Table 137. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 138. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 139. Berlin Cures Recent Development
Table 140. Eiger BioPharmaceuticals Corporation Information
Table 141. Eiger BioPharmaceuticals Description and Business Overview
Table 142. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 143. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 144. Eiger BioPharmaceuticals Recent Development
Table 145. Reata Pharmaceuticals Corporation Information
Table 146. Reata Pharmaceuticals Description and Business Overview
Table 147. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 148. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 149. Reata Pharmaceuticals Recent Development
Table 150. Production Base and Market Concentration Rate of Raw Material
Table 151. Key Suppliers of Raw Materials
Table 152. Pulmonary Arterial Hypertension (PAH) Drugs Distributors List
Table 153. Pulmonary Arterial Hypertension (PAH) Drugs Customers List
Table 154. Pulmonary Arterial Hypertension (PAH) Drugs Market Key Trends
Table 155. Pulmonary Arterial Hypertension (PAH) Drugs Key Opportunities and Drivers
Table 156. Pulmonary Arterial Hypertension (PAH) Drugs Market Challenges
Table 157. Research Programs/Design for This Report
Table 158. Key Data Information from Secondary Sources
Table 159. Key Data Information from Primary Sources
List of Figures
Figure 1. Pulmonary Arterial Hypertension (PAH) Drugs Product Picture
Figure 2. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Application in 2020 & 2026
Figure 6. Hospitals Examples
Figure 7. Clinics Examples
Figure 8. Other Examples
Figure 9. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) Growth Rate (2015-2026)
Figure 10. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$ Million) Growth Rate (2015-2026)
Figure 11. Global Pulmonary Arterial Hypertension (PAH) Drugs Price Trends Growth Rate (2015-2026) (USD/Pcs)
Figure 12. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region: 2015 VS 2020
Figure 13. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region: 2021 VS 2026
Figure 14. United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 15. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs) Growth Rate (2015-2026)
Figure 16. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 17. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 18. China Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. China Pulmonary Arterial Hypertension (PAH) Drugs Sales (Million USD) and Growth Rate (2015-2026)
Figure 20. Japan Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. Japan Pulmonary Arterial Hypertension (PAH) Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 22. Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 24. India Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. India Pulmonary Arterial Hypertension (PAH) Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 26. Global 5 Largest Pulmonary Arterial Hypertension (PAH) Drugs Players Market Share by Revenue in Pulmonary Arterial Hypertension (PAH) Drugs 2015 & 2019
Figure 27. Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 28. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Type (2015-2020)
Figure 29. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate by Type in 2015 & 2019
Figure 30. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Application (2015-2020)
Figure 31. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate by Application in 2015 & 2019
Figure 32. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type in 2019
Figure 33. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type in 2019
Figure 34. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Company in 2019
Figure 35. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type in 2019
Figure 36. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application in 2019
Figure 37. China Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Company in 2019
Figure 38. China Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type in 2019
Figure 39. China Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application in 2019
Figure 40. Japan Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Company in 2019
Figure 41. Japan Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type in 2019
Figure 42. Japan Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application in 2019
Figure 43. Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Company in 2019
Figure 44. Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type in 2019
Figure 45. Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application in 2019
Figure 46. India Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Company in 2019
Figure 47. India Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type in 2019
Figure 48. India Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application in 2019
Figure 49. Key Raw Materials Price Trend
Figure 50. Manufacturing Cost Structure of Pulmonary Arterial Hypertension (PAH) Drugs
Figure 51. Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH) Drugs
Figure 52. Pulmonary Arterial Hypertension (PAH) Drugs Industrial Chain Analysis
Figure 53. Channels of Distribution
Figure 54. Distributors Profiles
Figure 55. Porter's Five Forces Analysis
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
肺高血圧症治療薬の世界市場レポート2020 Market Analysis and Insights: Global Pulmonary Hypertension Drug Market The global Pulmonary Hypertension Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. Global Pulmonary Hypertension Drug Scope and Market Size The global…- 静脈動脈ECMOシステムの世界市場レポート2020 This report studies the Veno-Arterial ECMO System market. Veno-Arterial Extracorporeal Membrane Oxygenation (ECMO) Systems is a new treatment method aimed at heart and lung failure disease. Veno-Arterial ECMO transport is an effective method of transferring patients with severe ARDS. It has multiple…
- 動脈血管ステントの世界市場レポート2020 Market Analysis and Insights: Global Arterial Vascular Stent Market The global Arterial Vascular Stent market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. Global Arterial Vascular Stent Scope and Market Size The global Arterial Va…
- 経カテーテル肺動脈弁（TPV）の世界市場レポート2020 Market Analysis and Insights: Global Transcatheter Pulmonary Valve (TPV) Market The global Transcatheter Pulmonary Valve (TPV) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. Global Transcatheter Pulmonary Valve (TPV) Scope an…
- 肺動脈カテーテルの世界市場レポート2020 Pulmonary artery catheterization is a diagnostic procedure in which a small catheter is inserted through a neck, arm, chest, or thigh vein and maneuvered into the right side of the heart, in order to measure pressures at different spots in the heart. Market is concentrated. Edwards Lifesciences, Arg…